PT3307727T - Inibidores heterocíclicos de erk1 e erk2 e a sua utilização no tratamento de cancro - Google Patents
Inibidores heterocíclicos de erk1 e erk2 e a sua utilização no tratamento de cancroInfo
- Publication number
- PT3307727T PT3307727T PT167414119T PT16741411T PT3307727T PT 3307727 T PT3307727 T PT 3307727T PT 167414119 T PT167414119 T PT 167414119T PT 16741411 T PT16741411 T PT 16741411T PT 3307727 T PT3307727 T PT 3307727T
- Authority
- PT
- Portugal
- Prior art keywords
- erk2
- erk1
- cancer
- treatment
- heterocyclic inhibitors
- Prior art date
Links
- 101100226056 Dictyostelium discoideum erkA gene Proteins 0.000 title 1
- 101100226058 Dictyostelium discoideum erkB gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175756P | 2015-06-15 | 2015-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3307727T true PT3307727T (pt) | 2024-01-12 |
Family
ID=56497830
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT211560487T PT3842429T (pt) | 2015-06-15 | 2016-06-15 | Inibidores heterocíclicos de erk1 e erk2 e a sua utilização no tratamento de cancro |
| PT167414119T PT3307727T (pt) | 2015-06-15 | 2016-06-15 | Inibidores heterocíclicos de erk1 e erk2 e a sua utilização no tratamento de cancro |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT211560487T PT3842429T (pt) | 2015-06-15 | 2016-06-15 | Inibidores heterocíclicos de erk1 e erk2 e a sua utilização no tratamento de cancro |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9896445B2 (pt) |
| EP (2) | EP3842429B1 (pt) |
| JP (2) | JP6909729B2 (pt) |
| KR (2) | KR102644798B1 (pt) |
| CN (2) | CN107922387B (pt) |
| AU (2) | AU2016280717C1 (pt) |
| BR (1) | BR112017026159A2 (pt) |
| CA (1) | CA2986587C (pt) |
| DK (2) | DK3307727T3 (pt) |
| ES (2) | ES2968007T3 (pt) |
| FI (1) | FI3307727T3 (pt) |
| IL (1) | IL255613B (pt) |
| MX (2) | MX388641B (pt) |
| PL (2) | PL3307727T3 (pt) |
| PT (2) | PT3842429T (pt) |
| RU (1) | RU2017139727A (pt) |
| WO (1) | WO2016205418A1 (pt) |
| ZA (1) | ZA201707526B (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016205418A1 (en) | 2015-06-15 | 2016-12-22 | Asana Biosciences, Llc | Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer |
| EP3365334B1 (en) | 2015-10-21 | 2024-07-17 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| AU2018269982B2 (en) * | 2017-05-16 | 2024-06-13 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating cancer with atypical BRAF mutations |
| EP3805217A4 (en) * | 2018-06-08 | 2022-03-23 | Betta Pharmaceuticals Co., Ltd | ERK INHIBITOR AND ITS USE |
| CN109608444B (zh) * | 2018-11-27 | 2022-02-11 | 中国药科大学 | 含异吲哚啉酮的erk抑制剂及其制备方法与用途 |
| BR112021017957A2 (pt) | 2019-03-28 | 2021-11-23 | Jiangsu Hengrui Medicine Co | Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo |
| TW202102505A (zh) * | 2019-03-29 | 2021-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吡咯并雜環類衍生物、其製備方法及其在醫藥上的應用 |
| CA3158910A1 (en) * | 2019-10-28 | 2021-05-06 | Asana Biosciences, Llc | Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2 |
| CN111620860B (zh) * | 2020-06-23 | 2023-02-03 | 济南健丰化工有限公司 | 一种福瑞塞替的制备方法 |
| US20240285621A1 (en) * | 2020-09-23 | 2024-08-29 | Nerviano Medical Sciences S.R.L. | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
| CN114315837B (zh) * | 2020-09-29 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 一种erk抑制剂的结晶形式及其制备方法 |
| WO2022068860A1 (zh) * | 2020-09-29 | 2022-04-07 | 江苏恒瑞医药股份有限公司 | 一种吡咯并杂环类衍生物的晶型及其制备方法 |
| CA3215387A1 (en) * | 2021-04-16 | 2022-10-20 | Dawei XUAN | Uses of heterocyclic inhibitors of erk1/2 |
| US20240285624A1 (en) * | 2021-06-24 | 2024-08-29 | Erasca, Inc. | Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy |
| WO2022271939A1 (en) * | 2021-06-24 | 2022-12-29 | Erasca, Inc. | Erk1/2 and cdk4/6 inhibitors combination therapy |
| JP2024526135A (ja) * | 2021-06-24 | 2024-07-17 | エラスカ，インク． | Ｅｒｋ１／２阻害剤とｋｒａｓ ｇ１２ｃ阻害剤の併用療法 |
| MX2023015298A (es) * | 2021-06-24 | 2024-03-20 | Erasca Inc | Terapia de combinación de inhibidores de erk1/2 y shp2. |
| TW202341999A (zh) * | 2022-03-28 | 2023-11-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 吡咯并雜環類衍生物的富馬酸鹽的晶型及其製備方法 |
| WO2024064690A1 (en) * | 2022-09-20 | 2024-03-28 | Erasca, Inc. | Erk1/2 inhibitor polymorph forms |
| TW202440128A (zh) * | 2023-01-06 | 2024-10-16 | 美商艾瑞斯卡公司 | Raf抑制劑及erk1/2及/或shp2抑制劑組合療法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1319849B1 (it) | 2000-02-18 | 2003-11-03 | Angelo Dotta | Cerotto in confezione ad apertura rapida e mezzi per la realizzazionedella stessa. |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| US6743941B2 (en) | 2001-06-15 | 2004-06-01 | Aventis Pharma Deutschland Gmbh | Process for the production of piperidine derivatives |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| CA2547080A1 (en) | 2003-12-02 | 2005-07-28 | Vertex Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors and uses thereof |
| US20070191336A1 (en) | 2003-12-24 | 2007-08-16 | Flynn Daniel L | Anti-inflammatory medicaments |
| JP4993604B2 (ja) * | 2004-05-14 | 2012-08-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピロリルピリミジンｅｒｋプロテインキナーゼインヒビターのプロドラッグ |
| US7501415B2 (en) * | 2004-12-23 | 2009-03-10 | Vertex Pharmaceuticals Incorporated | Selective inhibitors of ERK protein kinase and uses thereof |
| US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
| MX2012005332A (es) * | 2009-11-13 | 2012-10-15 | Oscotec Inc | Inhibidores de cinasa. |
| WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| US9227969B2 (en) * | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| WO2016205418A1 (en) * | 2015-06-15 | 2016-12-22 | Asana Biosciences, Llc | Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer |
| TW201805000A (zh) | 2016-06-20 | 2018-02-16 | 庫拉腫瘤技術股份有限公司 | 利用erk抑制劑之鱗狀細胞癌之治療 |
| WO2020046966A1 (en) | 2018-08-27 | 2020-03-05 | Kura Oncology, Inc. | Treatment of adenocarcinomas with mapk pathway inhibitors |
| CA3158910A1 (en) | 2019-10-28 | 2021-05-06 | Asana Biosciences, Llc | Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2 |
| CA3215387A1 (en) | 2021-04-16 | 2022-10-20 | Dawei XUAN | Uses of heterocyclic inhibitors of erk1/2 |
-
2016
- 2016-06-15 WO PCT/US2016/037697 patent/WO2016205418A1/en not_active Ceased
- 2016-06-15 BR BR112017026159-6A patent/BR112017026159A2/pt not_active Application Discontinuation
- 2016-06-15 RU RU2017139727A patent/RU2017139727A/ru not_active Application Discontinuation
- 2016-06-15 JP JP2017559575A patent/JP6909729B2/ja active Active
- 2016-06-15 KR KR1020217005104A patent/KR102644798B1/ko active Active
- 2016-06-15 DK DK16741411.9T patent/DK3307727T3/da active
- 2016-06-15 FI FIEP16741411.9T patent/FI3307727T3/fi active
- 2016-06-15 PL PL16741411.9T patent/PL3307727T3/pl unknown
- 2016-06-15 PL PL21156048.7T patent/PL3842429T3/pl unknown
- 2016-06-15 US US15/183,486 patent/US9896445B2/en active Active
- 2016-06-15 CA CA2986587A patent/CA2986587C/en active Active
- 2016-06-15 AU AU2016280717A patent/AU2016280717C1/en active Active
- 2016-06-15 US US15/183,504 patent/US10751332B2/en active Active
- 2016-06-15 PT PT211560487T patent/PT3842429T/pt unknown
- 2016-06-15 MX MX2017014584A patent/MX388641B/es unknown
- 2016-06-15 EP EP21156048.7A patent/EP3842429B1/en active Active
- 2016-06-15 DK DK21156048.7T patent/DK3842429T3/da active
- 2016-06-15 EP EP16741411.9A patent/EP3307727B1/en active Active
- 2016-06-15 PT PT167414119T patent/PT3307727T/pt unknown
- 2016-06-15 ES ES16741411T patent/ES2968007T3/es active Active
- 2016-06-15 KR KR1020177034157A patent/KR102644788B1/ko active Active
- 2016-06-15 CN CN201680031963.5A patent/CN107922387B/zh active Active
- 2016-06-15 CN CN202110399513.4A patent/CN113200961B/zh active Active
- 2016-06-15 ES ES21156048T patent/ES2930050T3/es active Active
-
2017
- 2017-09-01 US US15/694,124 patent/US10471051B2/en active Active
- 2017-11-07 ZA ZA2017/07526A patent/ZA201707526B/en unknown
- 2017-11-12 IL IL255613A patent/IL255613B/en active IP Right Grant
- 2017-11-14 MX MX2021000148A patent/MX2021000148A/es unknown
-
2020
- 2020-02-13 US US16/790,082 patent/US11103491B2/en active Active
- 2020-11-19 AU AU2020273302A patent/AU2020273302B2/en active Active
-
2021
- 2021-03-16 JP JP2021042239A patent/JP7093438B2/ja active Active
- 2021-07-06 US US17/368,559 patent/US11925629B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255613B (en) | Heterocyclic inhibitors of erk1 and erk2 and their use in cancer therapy | |
| IL272948B1 (en) | enpp1 inhibitors and their use for cancer treatment | |
| IL256874B (en) | Immune checkpoint suppressors for use in the treatment of blood-borne cancers | |
| IL267455A (en) | Phosphodiesterase inhibitors and methods of treating bacteria | |
| IL259441B1 (en) | Materials and methods for the treatment of titin-based myopathies and other titinopathy | |
| IL262387B (en) | Arginase inhibitors and treatment applications thereof | |
| PT3362448T (pt) | Novos compostos inibidores da interação yap/taz-tead e sua utilização no tratamento do mesotelioma maligno | |
| SI3285803T1 (sl) | Postopki za zdravljenje in preprečevanje migrenskega glavobola | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| IL264451B1 (en) | A combination of abt-199 and achmetalstat for the treatment of aml | |
| SMT202100044T1 (it) | Composizioni comprendenti un inibitore della demetilasi-1 specifica per la lisina avente un anello pirimidinico e suo uso nel trattamento del cancro | |
| PL3240777T3 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| IL250484A0 (en) | Heterovesicular compounds and their use in the treatment of tuberculosis | |
| ZA201904966B (en) | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| GB201514021D0 (en) | Novel Pyridines and their use in the treatment of cancer | |
| IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| ZA201904967B (en) | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| PL3362450T3 (pl) | N1 i n7-podstawione pochodne sybiriliny oraz ich zastosowania jako inhibitory nekroptozy komórkowej | |
| GB201511799D0 (en) | Composition and methods of treatment | |
| GB201514015D0 (en) | Novel pyridazinones and their use in the treatment of cancer | |
| GB201605127D0 (en) | Composition and methods of treatment | |
| IL271211B1 (en) | Acetyl leucine for use in the treatment of migraine | |
| GB201710491D0 (en) | Composition and methods of treatment | |
| ZA201808008B (en) | Arginase inhibitors and their therapeutic applications | |
| GB201403086D0 (en) | Selection of virus and agent useful in the treatment of cancer |